RRR schreef op 25 februari 2016 11:49:
SHP623 for prophylactic treatment of HAE
SHP623 is a recombinant C1 inhibitor for the prophylactic treatment of HAE or other complement mediated diseases. SHP623 is intended to have a clinical profile similar to CINRYZE while providing manufacturing advantages and higher potency. In the fourth quarter of 2015, Shire received FDA approval of an IND to initiate a first-in-human study which is expected to be initiated in the first quarter of 2016.
ook Shire weet nu... Recombinant heeft de toekomst...
;-)